Walleye Capital
PCVX icon

Walleye Capital’s Vaxcyte PCVX Stock Holding History

Walleye Capital’s Portfolio PCVX Stock Details PCVX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-800
Closed -$65.5K – 4915
2024
Q4 		$65.5K Hold
800
– – ﹤0.01% 4287
2024
Q3 		$91.4K Buy
+800
New +$72.1K ﹤0.01% 4427
2024
Q2 		– Sell
-1,400
Closed -$95.6K – 5899
2024
Q1 		$95.6K Buy
1,400
+600
+75% +$41.5K ﹤0.01% 4415
2023
Q4 		$50.2K Buy
+800
New +$41.5K ﹤0.01% 4300
2023
Q3 		– Sell
-1,300
Closed -$64.9K – 5206
2023
Q2 		$64.9K Hold
1,300
– – ﹤0.01% 3572
2023
Q1 		$48.7K Sell
1,300
-1,300
-50% -$55.1K ﹤0.01% 3212
2022
Q4 		$125K Buy
+2,600
New +$102K ﹤0.01% 2283

Other funds holding PCVX

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Walleye Capital's PCVX Position: Q1 2026 in Review

Walleye Capital increased its Vaxcyte (PCVX) stake by 242% in Q1 2026, buying an estimated $1.95M and bringing the position to 50,650 shares worth $2.94M. The position accounts for 0.01% of the portfolio, ranked #1161.

Walleye Capital first reported a position in PCVX in Q1 2022 and has held it in 14 quarters since. The position peaked at $12.1M in Q4 2024. 336 funds tracked by Wall St. Rank hold PCVX as of Q1 2026.

  • Walleye Capital held 50,650 shares of Vaxcyte worth $2.94M as of Q1 2026.
  • Walleye Capital bought 35,845 Vaxcyte shares in Q1 2026, an estimated $1.95M.
  • Vaxcyte made up 0.01% of Walleye Capital's portfolio in Q1 2026, its #1161 holding.
  • Walleye Capital first reported a position in Vaxcyte in Q1 2022 and has held it in 14 quarters since.
  • Walleye Capital's Vaxcyte position peaked at $12.1M in Q4 2024.
  • 336 funds tracked by Wall St. Rank held Vaxcyte as of Q1 2026.

Based on Walleye Capital's 13F filing for Q1 2026, filed 11 May 2026.